# Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

> **NCT02730169** · PHASE2 · COMPLETED · sponsor: **Mereo BioPharma** · enrollment: 271 (actual)

## Conditions studied

- Hypogonadotropic Hypogonadism

## Interventions

- **DRUG:** BGS649
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02730169
- **Lead sponsor:** Mereo BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-12
- **Primary completion:** 2018-02-15
- **Final completion:** 2018-05-19
- **Target enrollment:** 271 (ACTUAL)
- **Last updated:** 2022-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02730169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02730169, "Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02730169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*